Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright boosted their FY2024 EPS estimates for Cardiol Therapeutics in a note issued to investors on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings per share of ($0.38) for the year, up from their previous forecast of ($0.44). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Cardiol Therapeutics' Q4 2024 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.
Cardiol Therapeutics Stock Up 3.2 %
NASDAQ CRDL traded up $0.05 on Friday, reaching $1.63. The stock had a trading volume of 321,814 shares, compared to its average volume of 420,347. Cardiol Therapeutics has a 1 year low of $0.79 and a 1 year high of $3.12. The business has a 50 day moving average price of $1.95 and a 200 day moving average price of $2.08. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $133.01 million, a price-to-earnings ratio of -4.04 and a beta of 0.91.
Institutional Trading of Cardiol Therapeutics
A number of hedge funds have recently modified their holdings of CRDL. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Cardiol Therapeutics in the 3rd quarter valued at $27,000. Townsquare Capital LLC acquired a new position in shares of Cardiol Therapeutics in the 3rd quarter worth approximately $27,000. Jane Street Group LLC acquired a new stake in Cardiol Therapeutics during the 3rd quarter valued at $29,000. Lion Street Advisors LLC raised its position in Cardiol Therapeutics by 7.9% in the 3rd quarter. Lion Street Advisors LLC now owns 273,281 shares of the company's stock valued at $544,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new stake in shares of Cardiol Therapeutics during the second quarter worth $59,000. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Articles
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
